Enzalutamide (Xtandi®) is indicated for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
|NCPE Assessment Process||Complete|
|Rapid review commissioned||18/12/2018|
|Rapid review completed||06/02/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of enzalutamide in combination with ADT compared with the current standard of care|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.